News

Allow e-prescribing of controlled drugs, key senators urge Obama administration

BY DSN STAFF

NEW YORK Having the endorsement of 11 senators around an issue that has become a bit of tripping stone for the wholesale adoption of e-prescribing suggests that a more comprehensive rollout of the cost- and time-saving capabilities associated with e-prescribing, and the advancements an overall healthcare information technology e-prescribing adoption will afford, could be just around the corner.

 

At the very least, allowing controlled substances to be included in e-prescribing protocols removes a pretty significant impediment for the widespread adoption of e-prescribing. So far e-prescribing is in use today in about 18% of doctor’s practices. And it’s a much harder sell for the remaining 82% when they’re being asked to make the investment in e-prescribing software and still also have to keep their prescription pads on hand for controlled substances and to maintain, essentially, two sets of files.

 

 

The fact of the matter is you can’t have a seamless HIT infrastructure, including electronic health records, without including controlled substances as part of that medical record. Not enabling doctors and pharmacists to follow patients on pain meds and other controlled medicines as closely as e-health allows is counterintuitive to the whole HIT movement.

 

 

Momentum has been building for physician adoption of e-prescribing. Surescripts last month announced that more than 100,000 physicians have jumped aboard the e-prescribing bandwagon, with some 74,000 doctors actively prescribing electronically in 2008 — up 100% versus 2007. If these 11 senators can push this measure through, you can expect that number to ramp up even more quickly.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Mylan co-founder Milan “Mike” Puskar to retire

BY DSN STAFF

PITTSBURGH The chairman of the board and co-founder of generic drug maker Mylan will retire from his position, Mylan announced Thursday.

Milan “Mike” Puskar will step down as chairman of the board, replaced by vice chairman and CEO Robert Coury. Puskar said he will retire as a director effective Oct. 1.

“On behalf of the board of directors and all of Mylan’s employees and shareholders, I would like to personally thank Mike Puskar for his many accomplishments; his impact on the industry; and for his service and leadership,” Coury said in a statement upon his election as board chairman. “Mike will truly, truly be missed.”

Puskar co-founded the company as a privately held drug distributor in 1961 with Don Panoz. He has been chairman of the board since 1993 and a director in the company for 33 years, serving as president from 1976 to 2000 and as CEO from 2000 to 2002.

“The time has come for met o step down as chairman, and I am more than confident that under Robert’s passionate and strategic direction, Mylan will continue to provide leadership for an industry that is continually evolving,” Puskar stated. “Robert has taken what we started almost 50 years ago and turned it into a global powerhouse with a vast reach that is unique among our peers.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Target reports April sales results

BY Allison Cerra

MINNEAPOLIS Target reported that its net retail sales for the four weeks ended May 2, 2009 were approximately $4.45 million, an increase of 4.5% from $4.25 million for the four weeks ended May 3, 2008.

On this same basis, April comparable-store sales increased 0.3%.

“April sales results were in line with our guidance for the month,” said Gregg Steinhafel, chairman, president and CEO Target Corp. “For the first quarter overall, retail segment financial performance was significantly better than expected, and the credit card segment performed in line with our prior guidance. As a result, we expect first quarter earnings per share results to be well above the current median First Call estimate of 52 cents.”

Year-to-date sales are approximately $14.36 million.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?